Next Article in Journal
Fumonisin B1 (FB1) Induces Lamellar Separation and Alters Sphingolipid Metabolism of In Vitro Cultured Hoof Explants
Next Article in Special Issue
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery
Previous Article in Journal
Maternal-Fetal Cancer Risk Assessment of Ochratoxin A during Pregnancy
Previous Article in Special Issue
Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessFeature PaperReview
Toxins 2016, 8(4), 88; doi:10.3390/toxins8040088

Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232-2765, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Hann-Chorng Kuo
Received: 27 January 2016 / Revised: 10 March 2016 / Accepted: 15 March 2016 / Published: 23 March 2016
(This article belongs to the Special Issue Botulinum Toxin A on Lower Urinary Tract Dysfunction)
View Full-Text   |   Download PDF [262 KB, uploaded 23 March 2016]

Abstract

Botulinum neurotoxin (BoNT) is used to treat a variety of ailments, and its therapeutic application in lower urinary tract disorders (LUTDs) is well studied. Robust evidence supporting the efficacy and tolerability of BoNT in the treatment of neurogenic detrusor overactivity (NDO) and non-neurogenic overactive bladder (OAB) has led to regulatory approval for these conditions. Use of BoNT in the treatment of interstitial cystitis/bladder pain syndrome, chronic pelvic pain, and detrusor sphincter dyssynergia has demonstrated some promise, but is still evolving and off-label for these indications. Trials to date do not support the use of BoNT for benign prostatic hyperplasia. This comprehensive review outlines the mechanisms of BoNT in the treatment of LUTDs in adults and presents background and updated data examining the efficacy and adverse events associated with the use of BoNT in common urologic applications. View Full-Text
Keywords: botulinum toxin; overactive bladder; neurogenic bladder; benign prostatic hyperplasia; detrusor sphincter dyssynergia; interstitial cystitis botulinum toxin; overactive bladder; neurogenic bladder; benign prostatic hyperplasia; detrusor sphincter dyssynergia; interstitial cystitis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Moore, D.C.; Cohn, J.A.; Dmochowski, R.R. Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins 2016, 8, 88.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top